Enzon Pharmaceuticals, Inc. announced earnings results for the third quarter ended September 30, 2019. For the third quarter, the company announced total revenue was USD 2,000 compared to negative total revenue of USD 280,000 a year ago. Operating loss was USD 325,000 compared to USD 519,000 a year ago. Net loss was USD 325,000 compared to USD 520,000 a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago. Diluted eps - continuing operations was USD 0 compared to diluted loss per share from continuing operations of USD 0.01 a year ago. For the nine months, total revenue was USD 158,000 compared to negative total revenue of USD 205,000 a year ago. Operating loss was USD 715,000 compared to USD 1.031 million a year ago. Net loss was USD 717,000 compared to USD 1.033 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.02 a year ago.